JPWO2015046563A1 - Soft capsule containing DHA and EPA - Google Patents
Soft capsule containing DHA and EPA Download PDFInfo
- Publication number
- JPWO2015046563A1 JPWO2015046563A1 JP2015539453A JP2015539453A JPWO2015046563A1 JP WO2015046563 A1 JPWO2015046563 A1 JP WO2015046563A1 JP 2015539453 A JP2015539453 A JP 2015539453A JP 2015539453 A JP2015539453 A JP 2015539453A JP WO2015046563 A1 JPWO2015046563 A1 JP WO2015046563A1
- Authority
- JP
- Japan
- Prior art keywords
- oil
- fish oil
- epa
- soft capsule
- dha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007901 soft capsule Substances 0.000 title claims abstract description 78
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 157
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 99
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 98
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 98
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 98
- 235000021323 fish oil Nutrition 0.000 claims abstract description 89
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 81
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 78
- 239000003921 oil Substances 0.000 claims abstract description 67
- 235000019198 oils Nutrition 0.000 claims abstract description 67
- 239000002775 capsule Substances 0.000 claims abstract description 36
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 44
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims description 37
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims description 37
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims description 35
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 32
- 235000007164 Oryza sativa Nutrition 0.000 claims description 22
- 235000009566 rice Nutrition 0.000 claims description 22
- 235000013339 cereals Nutrition 0.000 claims description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 17
- 229930003427 Vitamin E Natural products 0.000 claims description 16
- 235000019165 vitamin E Nutrition 0.000 claims description 16
- 239000011709 vitamin E Substances 0.000 claims description 16
- 229940046009 vitamin E Drugs 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 12
- 235000011803 sesame oil Nutrition 0.000 claims description 8
- 239000008159 sesame oil Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000944 linseed oil Substances 0.000 claims description 3
- 235000021388 linseed oil Nutrition 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 32
- 239000004615 ingredient Substances 0.000 abstract description 27
- 241000209094 Oryza Species 0.000 description 22
- 239000013589 supplement Substances 0.000 description 22
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 19
- 239000000047 product Substances 0.000 description 13
- 230000009467 reduction Effects 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- -1 drinks Substances 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 6
- 229930182558 Sterol Natural products 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 150000003432 sterols Chemical class 0.000 description 5
- 235000003702 sterols Nutrition 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000207961 Sesamum Species 0.000 description 3
- 235000003434 Sesamum indicum Nutrition 0.000 description 3
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- HNURKXXMYARGAY-UHFFFAOYSA-N 2,6-Di-tert-butyl-4-hydroxymethylphenol Chemical compound CC(C)(C)C1=CC(CO)=CC(C(C)(C)C)=C1O HNURKXXMYARGAY-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- RRTBTJPVUGMUNR-UHFFFAOYSA-N Cycloartanol Natural products C12CCC(C(C(O)CC3)(C)C)C3C2(CC)CCC2(C)C1(C)CCC2C(C)CCCC(C)C RRTBTJPVUGMUNR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 241001274189 Pomatomus saltatrix Species 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- YNBJLDSWFGUFRT-UHFFFAOYSA-N cycloartenol Natural products CC(CCC=C(C)C)C1CCC2(C)C1(C)CCC34CC35CCC(O)C(C)(C)C5CCC24C YNBJLDSWFGUFRT-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- KQRXQIPRDKVZPW-ISZNXKAUSA-N sesaminol Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-ISZNXKAUSA-N 0.000 description 2
- KQRXQIPRDKVZPW-UHFFFAOYSA-N sesaminol Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-UHFFFAOYSA-N 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- PZZKGQBMBVYPGR-UHFFFAOYSA-N η-tocopherol Chemical compound OC1=C(C)C=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 PZZKGQBMBVYPGR-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 description 1
- XZEUYTKSAYNYPK-UHFFFAOYSA-N 3beta-29-Norcycloart-24-en-3-ol Natural products C1CC2(C)C(C(CCC=C(C)C)C)CCC2(C)C2CCC3C(C)C(O)CCC33C21C3 XZEUYTKSAYNYPK-UHFFFAOYSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- OPAORDVBZRVVNQ-RNQWEJQRSA-N 4-[(z,2r)-4-(4-hydroxy-3-methoxyphenyl)-2,3-dimethylbut-3-enyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C[C@@H](C)C(\C)=C/C=2C=C(OC)C(O)=CC=2)=C1 OPAORDVBZRVVNQ-RNQWEJQRSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 description 1
- 241000962514 Alosa chrysochloris Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- DVJSDNKGCNXYQR-UHFFFAOYSA-N CO.[B] Chemical class CO.[B] DVJSDNKGCNXYQR-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- CIBNJPPYSPYHDB-UHFFFAOYSA-N Cyclobranol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCC(C)=C(C)C)C)CCC3(C)C1CC2 CIBNJPPYSPYHDB-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- HVXLSFNCWWWDPA-UHFFFAOYSA-N Isocycloartenol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCCC(C)=C)C)CCC3(C)C1CC2 HVXLSFNCWWWDPA-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- HXQRIQXPGMPSRW-UHZRDUGNSA-N Pollinastanol Natural products O[C@@H]1C[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@H]([C@H](CCCC(C)C)C)CC5)CC4)CC2)C3)CC1 HXQRIQXPGMPSRW-UHZRDUGNSA-N 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 241001504592 Trachurus trachurus Species 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- YABASAWVVRQMEU-YBXTVTTCSA-N cycloartanol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]3(C)[C@@H]1CC2 YABASAWVVRQMEU-YBXTVTTCSA-N 0.000 description 1
- ONQRKEUAIJMULO-YBXTVTTCSA-N cycloartenol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@@]3(C)[C@@H]1CC2 ONQRKEUAIJMULO-YBXTVTTCSA-N 0.000 description 1
- FODTZLFLDFKIQH-UHFFFAOYSA-N cycloartenol trans-ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OC2C(C3CCC4C5(C)CCC(C5(C)CCC54CC53CC2)C(C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-UHFFFAOYSA-N 0.000 description 1
- CIBNJPPYSPYHDB-UEBIAWITSA-N cyclobranol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CCC(C)=C(C)C)C)CC[C@@]3(C)[C@@H]1CC2 CIBNJPPYSPYHDB-UEBIAWITSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical group COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- GRONZTPUWOOUFQ-UHFFFAOYSA-M sodium;methanol;hydroxide Chemical compound [OH-].[Na+].OC GRONZTPUWOOUFQ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
既存製品のカプセルのサイズを大きくすることなく、既存製品に含まれるDHA、EPAの量は維持しながら、さらに他の健康成分を軟カプセル中に封入する。ドコサヘキサエン酸の含有率が50%以上となるように濃縮された魚油と、エイコサペンタエン酸の含有率が15%以上である魚油とを用い、これらを、他の健康成分である常温で液状の油と混合する。Without increasing the size of the capsule of the existing product, other health ingredients are encapsulated in the soft capsule while maintaining the amount of DHA and EPA contained in the existing product. Using fish oil concentrated so that the content of docosahexaenoic acid is 50% or more and fish oil having a content of eicosapentaenoic acid of 15% or more, these are oils that are liquid at room temperature as other health ingredients Mix with.
Description
本発明は、ドコサヘキサエン酸とエイコサペンタエン酸とを高濃度に含有し、さらに他の健康成分を含有する軟カプセルに関する。 The present invention relates to a soft capsule containing docosahexaenoic acid and eicosapentaenoic acid at a high concentration and further containing other health ingredients.
青魚などの魚油に含まれるドコサヘキサエン酸(DHA)及びエイコサペンタエン酸(EPA)は、動脈硬化や高脂血症などの生活習慣病の予防効果や、学習機能の向上効果があることが知られている。厚生労働省による「日本人の食事摂取基準」(2010年版)(非特許文献1)によれば、18歳以上におけるEPA及びDHAの望ましい1日当たり摂取量は1g以上とされているが、近年の食の欧米化に伴い、日本人の青魚などの魚介類消費量は減少しており、EPA及びDHAの望ましい量を摂取している人は少なくなっている。このような状況に鑑み、DHAやEPAを含有するサプリメントが市販されている。サプリメントには、ドリンク剤、錠剤、顆粒剤、散剤、硬カプセル剤、軟カプセル剤など多様な形態のものがあるが、携帯や保管に便利であり、また一定量の健康成分を簡便に摂取できる錠剤やカプセル剤はサプリメントの主流となっている。DHAやEPAのサプリメントに関しては、DHAやEPAが常温で液状の魚油に含まれる成分であり、魚油独特の匂いを発する可能性があること、また、酸化による劣化をうけやすく、加工の段階で失われる可能性があることから、複雑な工程を経ずにDHA・EPA含有魚油をそのまま封じ込めることができる軟カプセルの形態が好適である。出願人は、軟カプセル4粒に、DHA300mg、EPA100mgと、ゴマに含まれる希少な健康成分であるセサミン及び抗酸化作用のあるビタミンEとを含むサプリメント(カプセル1粒当たりの重量415mg)を製造、販売しており、2012年2月末時点で累計100万人以上といった多くのお客様にご愛飲いただいている。出願人は、上記のサプリメントのさらなる健康機能の向上にむけて鋭意検討を継続している。 Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) contained in fish oil such as blue fish are known to have preventive effects on lifestyle-related diseases such as arteriosclerosis and hyperlipidemia, and improve learning functions. Yes. According to the “Japanese Food Intake Criteria” by the Ministry of Health, Labor and Welfare (2010 edition) (Non-Patent Document 1), the preferred daily intake of EPA and DHA for those 18 years and older is 1 g or more. With the shift to westernization, the consumption of Japanese seafood such as blue fish is decreasing, and fewer people are taking the desired amount of EPA and DHA. In view of such circumstances, supplements containing DHA and EPA are commercially available. There are various types of supplements such as drinks, tablets, granules, powders, hard capsules, soft capsules, etc., but they are convenient to carry and store and can easily take in a certain amount of health ingredients. Tablets and capsules are the mainstream supplement. Regarding DHA and EPA supplements, DHA and EPA are components contained in fish oil that is liquid at room temperature, and may have a peculiar odor of fish oil, and are susceptible to deterioration due to oxidation and are lost at the processing stage. Therefore, a soft capsule form that can contain the DHA / EPA-containing fish oil as it is without a complicated process is preferable. The applicant manufactured a supplement (weighing 415 mg per capsule) containing 4 mg soft capsules, 300 mg DHA, 100 mg EPA, sesamin, a rare health ingredient contained in sesame, and vitamin E having an antioxidant effect, As of the end of February 2012, it has been enjoyed by many customers, including a cumulative total of over 1 million. The applicant has been continually studying to further improve the health function of the above supplement.
サプリメントは、一般に、日々継続して摂取することにより、体質等の改善がみられるものであるが、そのように日々継続して摂取するためには、消費者が服用しやすいこと(液剤、小粒の錠剤またはカプセルなど)、持ち運びや保管に便利であること(錠剤、カプセルなど)、価格が高くないことなどは、望ましい要素の1つであるといえる。また、錠剤やカプセルの場合、健康成分の所望の量をできるだけ少ない粒数で摂取できるものは、日々の飲みやすさの観点から望ましいといえる。また、サプリメントの愛用者の中には1日に数種類ものサプリメントを、何粒も(例えば10粒以上)服用する場合もあるが、1粒のサプリメント中に、より多くの種類の健康成分を、より多くの量含むものがあれば、1日に服用するサプリメントの数(種類)や粒数を減らすことができる場合もあると考えられ、望ましいと考えられる。 In general, supplements can be improved daily by daily consumption. However, in order to continue daily intake of such supplements, it is easy for consumers to take (solutions, small granules). (Tablets or capsules), convenience in carrying and storage (tablets, capsules, etc.), low price, etc. are desirable factors. In the case of tablets and capsules, it is desirable from the viewpoint of ease of daily drinking that a desired amount of health ingredients can be taken in as few grains as possible. In addition, some supplement users may take several kinds of supplements a day (for example, 10 or more), but more kinds of health ingredients in one supplement, If there is something that contains a larger amount, it may be possible to reduce the number (type) of supplements and the number of grains taken in a day, which is desirable.
このような状況に鑑み、出願人は、上記のサプリメント(軟カプセル)において、現在含まれている健康成分(4粒当たりDHA300mg、EPA100mg、セサミン、ビタミンE)の量はそのままで、さらに新たな健康成分を加えることを検討した。 In view of such a situation, the applicant, in the above-mentioned supplement (soft capsule), the amount of health ingredients (DHA 300 mg, EPA 100 mg, sesamin, vitamin E per 4 capsules) contained in the supplement is still unchanged, and a new health Consider adding ingredients.
DHAやEPAは、常温で液状の油(精製魚油)として得られるものであって、一定の容量(体積)を有するものであるから、軟カプセルといったある特定の容量を有するいわば「容器」の中に、既存の製品のDHA及びEPAの量を維持しつつ、さらに他の健康成分(特に油のような一定の容量を持つもの)を加えることは容易ではない。カプセルのサイズを大きくすれば可能ではあるが、消費者が服用しにくくなるため、好ましくない。 DHA and EPA are obtained as liquid oil (refined fish oil) at room temperature and have a certain volume (volume), so in a so-called “container” having a certain capacity such as soft capsules. In addition, it is not easy to add other health ingredients (especially those with a certain capacity such as oil) while maintaining the amount of DHA and EPA of existing products. Although it is possible to increase the size of the capsule, it is not preferable because it is difficult for consumers to take.
本発明は、カプセルのサイズを大きくすることなく、既存の製品に含まれるDHA、EPAの量は維持しながら、さらに他の健康成分(特に油のような一定の容量を持つもの)を軟カプセル中に封入して、軟カプセルのサプリメントとしての価値を高めること、または、飲みやすさ(大きさ、1日当たり粒数)を維持しつつ健康機能を高めることのできる技術を提供することを目的とする。 The present invention softens other health ingredients (especially those having a certain volume such as oil) while maintaining the amount of DHA and EPA contained in existing products without increasing the size of the capsule. The purpose is to provide a technology that can be encapsulated inside to increase the value as a supplement of soft capsules, or to enhance health functions while maintaining ease of drinking (size, number of grains per day) To do.
上記目的を達成するために、まず、精製魚油に含まれるDHA及びEPAの濃縮を試みたが、これらはいずれかを濃縮するともう一方の濃度が低減する傾向があることが判った。そのため、例えば、4粒当たりにDHA300mg、EPA100mg、さらに他の健康成分を含有する軟カプセルを、カプセルのサイズを現行品より大きくすることなく製造することは困難であった。特にEPAは、最高でも含有率30%程度の精製魚油が得られるのみであり、所望の量のEPAを含有する魚油を軟カプセル中に封入しようとすると、EPA精製魚油のみで軟カプセルの容量の多くを占めることとなり、DHAや他の健康成分を特定量で封入することが困難であった。しかしながら、鋭意検討を進めた結果、DHAを特定の濃度にまで濃縮した精製魚油中には、一定量のEPAが含まれることを見出し、このDHA濃縮精製魚油を、EPA精製魚油と組み合わせることで、軟カプセルの形状を大きくすることなく、DHAとEPAを目標の量(例えば、4粒当たりそれぞれ300mg及び100mg)で含み、さらに他の健康成分(例えば油のような一定の容量を有する成分)も含む軟カプセルを製造できることを見出した。本発明は、以下の態様を含む。
1.軟カプセル1粒当たりにドコサヘキサエン酸75mg以上と、エイコサペンタエン酸とを含有する魚油を含み、さらに、常温で液状の魚油以外の油を含む、カプセル皮膜以外の重量が220mg〜260mgの軟カプセルの製造方法であって、
ドコサヘキサエン酸の含有率が50%以上となるように濃縮された魚油と、エイコサペンタエン酸の含有率が15%以上である魚油と、これら以外の常温で液状の油とを混合すること、
混合した油を軟カプセルの皮膜で包んで、内容量(カプセル皮膜以外の重量)が、220mg〜260mgの軟カプセルとすること、
を含む、上記方法。
2.前記エイコサペンタエン酸の含有率が15%以上である魚油として、エイコサペンタエン酸の含有率が25%以上となるように濃縮された魚油を用いる、上記1の方法。
3.軟カプセルが、1粒当たりにエイコサペンタエン酸を25mg以上含有する、上記1または2の方法。
4.ドコサヘキサエン酸の含有率が50%以上となるように濃縮された魚油が、エイコサペンタエン酸を5%以上の含有率で含む、上記1〜3のいずれか1の方法。
5.軟カプセル全体の重量(内容量とカプセル皮膜の重量の合計)が、380mg〜420mgである、上記1〜4のいずれか1の方法。
6.常温で液状の魚油以外の油が、米胚芽油、亜麻仁油、荏胡麻油、オリーブ油、胡麻油またはこれらのうちの2種以上の混合物を含む、上記1〜5のいずれか1の方法。
7.軟カプセルが、常温で液状の魚油以外の油を、カプセル1粒当たり20mg以上含む、上記1〜6のいずれか1の方法。
8.軟カプセルが、常温で液状の魚油以外の油を、カプセル1粒当たり20〜60mg含む、上記7の方法。
9.さらに、ビタミンEを混合することを含む、上記1〜8のいずれか1の方法。
10.さらに、セサミンを混合することを含む、上記1〜9のいずれか1の方法。
11.1粒当たりにドコサヘキサエン酸75mg以上、エイコサペンタエン酸25mg以上、及びγ−オリザノールを含む、1粒当たりの重量が380mg〜420mgである軟カプセル。In order to achieve the above object, first, concentration of DHA and EPA contained in refined fish oil was tried, but it was found that the concentration of either of them tends to decrease the other concentration. Therefore, for example, it has been difficult to produce soft capsules containing DHA 300 mg, EPA 100 mg, and other health ingredients per four grains without making the capsule size larger than the current product. In particular, EPA can only provide purified fish oil with a content rate of about 30% at the maximum. When trying to enclose a fish oil containing a desired amount of EPA in a soft capsule, the volume of the soft capsule can be increased with only EPA purified fish oil. It occupied a lot, and it was difficult to encapsulate DHA and other health ingredients in specific amounts. However, as a result of diligent investigation, it was found that a certain amount of EPA is contained in the refined fish oil obtained by concentrating DHA to a specific concentration, and by combining this DHA enriched refined fish oil with the EPA refined fish oil, Without increasing the size of the soft capsule, DHA and EPA are included in target amounts (eg, 300 mg and 100 mg per 4 tablets, respectively), and other health ingredients (eg, ingredients with a certain volume such as oil) are also available It has been found that soft capsules can be produced. The present invention includes the following aspects.
1. Production of soft capsules containing a fish oil containing 75 mg or more of docosahexaenoic acid and eicosapentaenoic acid per soft capsule, and further containing oil other than liquid fish oil at room temperature and having a weight other than the capsule film of 220 mg to 260 mg A method,
Mixing fish oil concentrated so that the content of docosahexaenoic acid is 50% or more, fish oil having a content of eicosapentaenoic acid of 15% or more, and liquid oil at room temperature other than these,
Wrapping the mixed oil with a soft capsule film to make a soft capsule having an inner volume (weight other than the capsule film) of 220 mg to 260 mg,
Including the above method.
2. The method according to 1 above, wherein the fish oil concentrated so that the content of eicosapentaenoic acid is 25% or more is used as the fish oil having a content of eicosapentaenoic acid of 15% or more.
3. The method of 1 or 2 above, wherein the soft capsule contains 25 mg or more of eicosapentaenoic acid per grain.
4). The method according to any one of the above 1 to 3, wherein the fish oil concentrated so that the content of docosahexaenoic acid is 50% or more contains eicosapentaenoic acid at a content of 5% or more.
5. 5. The method according to any one of 1 to 4 above, wherein the total weight of the soft capsule (the total amount of the internal volume and the capsule film) is 380 mg to 420 mg.
6). The method according to any one of 1 to 5 above, wherein the oil other than fish oil that is liquid at normal temperature comprises rice germ oil, linseed oil, sesame oil, olive oil, sesame oil, or a mixture of two or more thereof.
7). The method according to any one of 1 to 6 above, wherein the soft capsule contains 20 mg or more of oil other than fish oil that is liquid at normal temperature per capsule.
8). 8. The method according to 7 above, wherein the soft capsule contains 20 to 60 mg of oil other than fish oil that is liquid at normal temperature per capsule.
9. The method according to any one of 1 to 8, further comprising mixing vitamin E.
10. The method according to any one of 1 to 9, further comprising mixing sesamin.
11. A soft capsule having a weight per grain of 380 mg to 420 mg, containing 75 mg or more of docosahexaenoic acid, 25 mg or more of eicosapentaenoic acid, and γ-oryzanol per 11.1 grain.
本発明によれば、1粒当たりのサイズ、ならびに1粒に含まれるDHA及びEPAの量を維持しながら、さらに追加の健康成分(常温で液状の油の形態の健康成分)を軟カプセル中に含有させることができ、軟カプセルのサプリメントとしての価値を高めることができる。具体的には、1粒当たりのサイズが、比較的小さいので服用しやすく、また、DHAとEPAに加えて追加の健康成分を含むので、さらなる健康効果が期待できる。また、1粒当たりの健康成分の含有量が高いので、1日当たりの服用粒数が、比較的少なくて済む(目安として4粒)。サプリメントが多種類の健康成分を含むことは、健康を志向する消費者にとって利益である。また、1日当たり服用粒数が少なくて済むことは、消費者が手軽に服用できるという利点に加え、通常、1ヶ月単位などで容器に詰められて販売されるサプリメントにおいて、商品(例えば1ヶ月分のサプリメントを入れた容器)の大きさが大きくならずに済み、消費者と販売者の双方にとって運搬や保管の際に利点があるといえる。また、サプリメントしての役割を考えると、サプリメントの摂取による健康成分以外の成分の摂取はできるだけ少ない方が望ましいといえるところ、1日当たりに服用する軟カプセルの粒数が少なければ、その分、カプセルの皮膜などの健康成分以外の成分の1日当たりの摂取量が減ると考えられ、好ましいと考えられる。 According to the present invention, while maintaining the size per grain and the amount of DHA and EPA contained in each grain, additional health ingredients (health ingredients in the form of liquid oil at room temperature) are further contained in the soft capsule. It can be contained, and the value as a supplement of a soft capsule can be increased. Specifically, since the size per grain is relatively small, it is easy to take, and since additional health ingredients are included in addition to DHA and EPA, further health effects can be expected. In addition, since the content of health ingredients per grain is high, the number of grains taken per day is relatively small (4 as a guide). It is beneficial for health-conscious consumers that the supplement contains many types of health ingredients. In addition, the fact that the number of grains taken per day is small, in addition to the advantage that consumers can easily take, in addition to the products (for example, for one month) in supplements that are usually packed and sold in containers in units of one month. The size of the container containing the supplement is not increased, which is advantageous for both consumers and sellers during transportation and storage. In addition, considering the role of supplements, it can be said that it is desirable to consume as little as possible of ingredients other than health ingredients by taking supplements. However, if the number of soft capsules to be taken per day is small, the corresponding amount It is considered that the daily intake of components other than health components such as the film of this skin is reduced, which is preferable.
本発明は、特定の量以上のドコサヘキサエン酸及びエイコサペンタエン酸を含む魚油を含有し、さらにこの魚油以外の常温で液状の油を含有する、カプセル皮膜以外の重量(すなわち、カプセル中に含まれる液量)が220mg〜260mgの軟カプセルを製造する方法に関する。本発明の方法は、ドコサヘキサエン酸の含有率が50%以上となるように濃縮された油を用いることを特徴の1つとする。 The present invention contains a fish oil containing a specific amount or more of docosahexaenoic acid and eicosapentaenoic acid, and further contains a liquid oil at room temperature other than the fish oil (ie, a liquid contained in the capsule). The present invention relates to a method for producing soft capsules having an amount of 220 to 260 mg. One of the features of the method of the present invention is to use oil concentrated so that the content of docosahexaenoic acid is 50% or more.
(ドコサヘキサエン酸、エイコサペンタエン酸)
ドコサヘキサエン酸(DHA)は、分子式C22H32O2の不飽和脂肪酸である。エイコサペンタエン酸(EPA)は、分子式C20H30O2の不飽和脂肪酸である。これらはいずれも魚油中に多く含まれることが知られている(例えば、イワシ油:DHA12%、EPA17%、マグロ油:DHA25%、EPA7%、カツオ油:DHA24%、EPA5%、サケ油:DHA14%、EPA9%)。本発明では、容量の限定された軟カプセル中に、特定量以上のDHA及びEPAを配合するために、これらをそれぞれ特定濃度以上とした魚油を組み合わせて用いる。具体的には、DHAの含有率が50%以上となるように濃縮された魚油と、EPAの含有率が15%以上である魚油とを組み合わせる。なお、本発明において、DHA及びEPAの含有量は、遊離脂肪酸としてのDHA及びEPAの量のみではなく、トリグリセリド、ジグリセリド、またはモノグリセリドの形態にあるDHA及びEPAの量(遊離脂肪酸量に換算する)も含むものとする。魚油中のDHA及びEPAのそれぞれの含有率または含有量は、以下の実施例に詳細を示すように、GC(ガスクロマトグラフィー)を用いて測定することができる。(Docosahexaenoic acid, eicosapentaenoic acid)
Docosahexaenoic acid (DHA) is an unsaturated fatty acid of the molecular formula C 22 H 32 O 2 . Eicosapentaenoic acid (EPA) is an unsaturated fatty acid molecular formula C 20 H 30 O 2. All of these are known to be contained in a large amount in fish oil (for example, sardine oil: DHA 12%, EPA 17%, tuna oil: DHA 25%, EPA 7%, skipjack oil: DHA 24%, EPA 5%, salmon oil: DHA14 %, EPA 9%). In this invention, in order to mix | blend DHA and EPA more than a specific amount in the soft capsule with capacity | capacitance limited, these are used combining the fish oil which made these each more than a specific density | concentration. Specifically, fish oil concentrated so that the DHA content is 50% or more and fish oil having an EPA content of 15% or more are combined. In the present invention, the contents of DHA and EPA are not only the amounts of DHA and EPA as free fatty acids, but also the amounts of DHA and EPA in the form of triglycerides, diglycerides, or monoglycerides (converted to the amount of free fatty acids). Shall also be included. The respective contents or contents of DHA and EPA in fish oil can be measured using GC (gas chromatography) as shown in detail in the following examples.
魚油中のDHAやEPAを濃縮する方法については例えば、基質特異性のあるリパーゼを用いて、所望の脂肪酸以外の脂肪酸を除去する方法が挙げられ、そのような方法については種々報告されている(例えば、特開平8−214891号公報、特開2002−136298号公報、特許第4530311号、特許第5204776号、特開2013−55893号公報)。本発明では、いずれかの方法で所望の濃度とした精製魚油を用いることができる。DHAやEPAは酸化されやすい成分であるから、魚油としては、新鮮な魚から得られた油を用いることが重要である。魚の種類は特に限定されないが、マグロ、カツオ、イワシ、サバ、サンマ、アジ、イカ、タラなどから得られる油は、DHAやEPAを豊富に含むので好ましい。 Examples of the method for concentrating DHA and EPA in fish oil include a method of removing fatty acids other than a desired fatty acid using a lipase having a substrate specificity, and such methods have been reported in various ways ( For example, Unexamined-Japanese-Patent No. 8-214891, Unexamined-Japanese-Patent No. 2002-136298, Japanese Patent No. 4530311, Japanese Patent No. 5204776, Unexamined-Japanese-Patent No. 2013-55893). In the present invention, purified fish oil having a desired concentration by any method can be used. Since DHA and EPA are easily oxidized components, it is important to use oil obtained from fresh fish as fish oil. The type of fish is not particularly limited, but oils obtained from tuna, bonito, sardines, mackerel, saury, horse mackerel, squid, cod and the like are preferable because they contain abundant DHA and EPA.
EPA精製魚油としては、EPAの含有率が15%以上であるものを用いる。好ましくは、EPAの含有率を25%以上に濃縮した魚油(EPA精製濃縮魚油)を用いる。本発明において、EPA精製魚油としては、精製品または濃縮精製魚油を適宜用いることができる。EPA濃縮精製魚油中の上限値は特に制限されないが、上記の方法によって精製したEPA濃縮精製魚油中のEPAの含有率は、最高でも30%程度であると考えられる。所定の容量の軟カプセル中に、所定量のEPAを含有させるためには、DHAの濃度を高めるように精製した魚油(DHA濃縮精製魚油)中に含まれるEPAも考慮に入れる必要がある。DHA濃縮精製魚油中のDHA含有率は、75%程度まで高められたものも存在する。しかしながら、DHAを高濃度に濃縮し過ぎると、DHA濃縮精製魚油中に含まれるEPAの濃度が低下して、軟カプセル中に必要な量のEPAをDHA濃縮精製魚油から補うことが困難となる。また、DHAを高濃度に濃縮した魚油はコストが高い。DHAの含有率の上限としては、70%程度、好ましくは60%程度までのものがよいであろう。特に、DHAの含有率が50%〜60%の範囲となるように濃縮されたDHA濃縮精製魚油中には、含有率で5%以上、好ましくは5%〜8%程度のEPAも残存しており、EPA精製魚油からのEPAと組み合わせることで、軟カプセル中に含有させるEPAの所定量を達成することができる。中でも、DHAの含有率が53%〜58%の範囲であり、および/または、EPAの含有率が6.5%〜7%の範囲のDHA濃縮精製魚油を好適に用いることができる。 As the EPA refined fish oil, one having an EPA content of 15% or more is used. Preferably, fish oil (EPA refined concentrated fish oil) in which the content of EPA is concentrated to 25% or more is used. In the present invention, as the EPA refined fish oil, a purified product or a concentrated refined fish oil can be appropriately used. The upper limit value in the EPA concentrated and refined fish oil is not particularly limited, but the content of EPA in the EPA concentrated and refined fish oil purified by the above method is considered to be about 30% at the maximum. In order to contain a predetermined amount of EPA in a predetermined volume of soft capsules, it is necessary to take into account EPA contained in fish oil refined to increase the concentration of DHA (DHA concentrated refined fish oil). Some DHA concentration in the DHA-concentrated and refined fish oil has been increased to about 75%. However, if DHA is concentrated to a high concentration too much, the concentration of EPA contained in the DHA-concentrated and refined fish oil decreases, making it difficult to supplement the amount of EPA required in the soft capsule from the DHA-concentrated and refined fish oil. Further, fish oil obtained by concentrating DHA at a high concentration is expensive. The upper limit of the DHA content should be about 70%, preferably up to about 60%. In particular, in DHA-concentrated and refined fish oil concentrated so that the DHA content is in the range of 50% to 60%, EPA with a content of 5% or more, preferably about 5% to 8% remains. In combination with EPA from EPA refined fish oil, a predetermined amount of EPA to be contained in the soft capsule can be achieved. Among them, DHA concentrated refined fish oil having a DHA content of 53% to 58% and / or a EPA content of 6.5% to 7% can be suitably used.
DHA濃縮精製魚油と、EPA精製魚油とは、必要に応じて100メッシュ〜120メッシュ程度の網を通過させて、適度な温度に保ちながら、撹拌混合すればよい。温度は、高すぎるとDHA及びEPAが劣化するおそれがある。好ましくは、30〜40℃の範囲である。また、撹拌は、魚油中にできるだけ酸素を巻き込まないように行うべきであり、窒素を吹き込みながら行うのが好ましい。 The DHA concentrated refined fish oil and the EPA refined fish oil may be stirred and mixed while passing through a net of about 100 mesh to 120 mesh as necessary and kept at an appropriate temperature. If the temperature is too high, DHA and EPA may deteriorate. Preferably, it is the range of 30-40 degreeC. Further, the stirring should be performed so as not to involve oxygen as much as possible in the fish oil, and is preferably performed while blowing nitrogen.
本発明の軟カプセル中には、1粒当たり、DHA75mg以上を含有させ、さらに、好ましくはEPA25mg以上を含有させる。これは、軟カプセル4粒で、DHA300mg、EPA100mgとなる量である。厚生労働省の「日本人の食事摂取基準」(2010年版)によれば、18歳以上におけるEPA及びDHAの望ましい1日当たり摂取量は1g以上であるが、EPA及びDHAの摂取量の最も少ない群(18〜29歳の女性)では1日当たり摂取量が188mgであり、最も多い群(70歳以上の男性)でも775mgである。EPA及びDHAは、現状、各世代の男女において1日当たり所望量に達していない。本発明の軟カプセルは、EPA及びDHAの摂取を補助する役割を果たす。なお、EPA及びDHAの1日当たりの摂取量の上限値は、「日本人の食事摂取基準」(2010年版)では算定されていない。しかしながら、どのような物質であれ、極端な大量摂取は健康障害を引き起こす可能性があるから、適度な量を保って摂取することが大切である。 In the soft capsule of the present invention, 75 mg or more of DHA is contained per grain, and more preferably 25 mg or more of EPA. This is an amount of 4 soft capsules to give 300 mg DHA and 100 mg EPA. According to the Ministry of Health, Labor and Welfare's “Japanese dietary intake standards” (2010 edition), the preferred daily intake of EPA and DHA for those over 18 years old is 1 g or more, but the group with the lowest EPA and DHA intake ( (18-29 year old female) has a daily intake of 188 mg, and the most common group (70 year old male) is 775 mg. EPA and DHA currently do not reach the desired amount per day for each generation of men and women. The soft capsule of the present invention plays a role in assisting ingestion of EPA and DHA. The upper limit of daily intake of EPA and DHA is not calculated in the “Japanese dietary intake standard” (2010 edition). However, it is important to keep an appropriate amount of any substance, because an extremely large amount can cause health problems.
DHA、EPAを日々適度な量で摂取することにより、心血管リスク低減、中性脂肪低下作用、関節リウマチ症状緩和作用、加齢黄斑変性症発生リスク低減、認知機能低下抑制効果等の幅広い効能が得られることが知られている。 By taking DHA and EPA in appropriate amounts every day, it has a wide range of effects such as cardiovascular risk reduction, triglyceride reduction, rheumatoid arthritis symptom reduction, age-related macular degeneration risk reduction, cognitive function reduction suppression It is known to be obtained.
(魚油以外に添加する成分)
本発明の軟カプセルには、上記のDHA、EPAを含有する魚油に加えて、魚油以外の常温で液状の油、特に健康機能を有するものをさらに配合する。本発明では、特定の濃度にまで凝縮したDHA濃縮精製魚油を、EPA精製魚油と組み合わせることにより、一定の容量を有する軟カプセル中にDHAとEPAとを所定量以上含有させつつ、さらに、他の健康機能を有する油も追加できることを見出した。(Ingredients added in addition to fish oil)
In addition to the fish oil containing DHA and EPA, the soft capsule of the present invention is further blended with a liquid oil at room temperature other than fish oil, particularly one having a health function. In the present invention, DHA-concentrated and refined fish oil condensed to a specific concentration is combined with EPA-purified fish oil, so that a predetermined amount or more of DHA and EPA are contained in a soft capsule having a certain volume, We found that oils with health functions can also be added.
本発明の軟カプセル中に配合するのに適する常温で液状の油としては、健康機能を有するものであれば特に限定されず、例えば、米胚芽油、亜麻仁油、荏胡麻油、オリーブ油、胡麻油、またはこれらを混合したものなどが挙げられる。米胚芽油は、好ましい油の1つである。米胚芽油は、米の胚芽から抽出された脂肪油であり、通常、1.0〜1.5w/w%程度のγ−オリザノールを含むと言われている。米胚芽油は、例えば、γ−オリザノールを1.2〜1.5w/w%含有するオリザオイルS−1(一丸ファルコス株式会社)、γ−オリザノールを1.0〜1.5w/w%含有する米胚芽油PRO−15(築野食品工業株式会社)等の名称で市販されている。 The oil at room temperature suitable for blending in the soft capsule of the present invention is not particularly limited as long as it has a health function. For example, rice germ oil, linseed oil, sesame sesame oil, olive oil, sesame oil, or The thing etc. which mixed these are mentioned. Rice germ oil is one preferred oil. Rice germ oil is a fatty oil extracted from rice germ and is usually said to contain about 1.0 to 1.5 w / w% of γ-oryzanol. Rice germ oil contains, for example, oryzal oil S-1 (Ichimaru Falcos Co., Ltd.) containing 1.2 to 1.5 w / w% of γ-oryzanol and 1.0 to 1.5 w / w% of γ-oryzanol. The rice germ oil PRO-15 (Tsukino Food Industry Co., Ltd.) is commercially available.
本願明細書において、γ−オリザノールとは、フェルラ酸にトリテルペンアルコール又はステロールがエステル結合したものの総称を指し、トリテルペンアルコールとしては、例えば、シクロアルテノール、2,4−メチレンシクロアルタノール、シクロアルタノール、シクロブラノール等を挙げることができ、ステロールとしては、例えば、カンペステロール、スチグマステロール、β−シトステロール等を挙げることができる。γ−オリザノールは、これらの化合物の混合物であってもよいし、単独の化合物であってもよい。γ−オリザノールには、血中中性脂質低下作用(Geriant. Med. 19, 1812-1840, 1981)、内分泌・自律神経調節作用(日薬理誌、75(4)、399-403, 1979)、胃粘膜保護作用(日薬理誌、84(6)、537-542, 1984)などの様々な生理作用が知られており、精製されたものは高脂血症治療剤や心身症(更年期障害、過敏性大腸症候群)治療剤などの医薬品として認可されている。γ−オリザノールの定量法としては、UV吸光度法やHPLC法等の公知の方法を適宜用いることができる。例えば、「医薬部外品原料規格」や「化学的合成品以外の食品添加物自主規格」に記載されている通り、サンプルをヘプタンに溶解し、315nm付近における吸収の極大波長で吸光度を測定することにより定量することができる。 In the present specification, γ-oryzanol refers to a generic name of triterpene alcohol or sterol ester-bonded to ferulic acid. Examples of triterpene alcohol include cycloartenol, 2,4-methylenecycloartanol, and cycloartanol. , Cyclobranol and the like, and examples of the sterol include campesterol, stigmasterol, β-sitosterol and the like. γ-oryzanol may be a mixture of these compounds or a single compound. In γ-oryzanol, blood neutral lipid lowering action (Geriant. Med. 19, 1812-1840, 1981), endocrine / autonomic nerve regulating action (Japanese Pharmacology, 75 (4), 399-403, 1979), Various physiological effects such as gastric mucosal protective action (Nippon Pharmacological Journal, 84 (6), 537-542, 1984) are known, and purified products are used to treat hyperlipidemia and psychosomatic disorders (menopause, It is approved as a medicine for treating irritable bowel syndrome. As a method for quantifying γ-oryzanol, a known method such as a UV absorbance method or an HPLC method can be appropriately used. For example, the sample is dissolved in heptane and the absorbance is measured at the maximum wavelength of absorption near 315 nm as described in “Standards for raw materials of quasi drugs” and “Voluntary standards for food additives other than chemically synthesized products”. Can be quantified.
米胚芽油は、γ−オリザノールを濃縮したものを用いても良い。濃縮油中のγ−オリザノールの含有量は、2w/w%以上が好ましく、30w/w%以上がより好ましい。このようなγ−オリザノールの濃縮油は、工業的には、有機溶剤で抽出するか、または樹脂処理後に精製することにより得ることができ、米胚芽油ガンマ30(築野食品工業株式会社)や、γ−オリザノール、オリザドリムV−50、コメヌカ油、玄米胚芽油(オリザ油化株式会社)として入手可能である。 As the rice germ oil, γ-oryzanol concentrated may be used. The content of γ-oryzanol in the concentrated oil is preferably 2 w / w% or more, and more preferably 30 w / w% or more. Such a concentrated oil of γ-oryzanol can be industrially obtained by extraction with an organic solvent or purification after resin treatment, such as rice germ oil gamma 30 (Tsukino Food Industry Co., Ltd.) , Γ-oryzanol, oryzadorim V-50, rice bran oil, brown rice germ oil (Oryza Oil Co., Ltd.).
軟カプセル中の米胚芽油の含有量は、米胚芽油または米胚芽油濃縮物に特徴的に含まれるステロールの含有量、及び各種ステロールの含有比率を指標として測定することができる。 The content of the rice germ oil in the soft capsule can be measured by using the sterol content characteristically contained in the rice germ oil or the rice germ oil concentrate and the content ratio of various sterols as an index.
米胚芽油の好ましい配合量は、本発明の軟カプセル1粒当たりに、1〜40mgであり、さらに好ましくは1〜20mg、最も好ましくは5〜10mgである。γ−オリザノールの好ましい配合量は、本発明の軟カプセル1粒当たりに、0.3〜12mgであり、さらに好ましくは0.3〜6mg、最も好ましくは1.5〜3mgである。 The preferable compounding amount of rice germ oil is 1 to 40 mg, more preferably 1 to 20 mg, and most preferably 5 to 10 mg per one soft capsule of the present invention. The preferable amount of γ-oryzanol is 0.3 to 12 mg, more preferably 0.3 to 6 mg, most preferably 1.5 to 3 mg per soft capsule of the present invention.
米胚芽油などの、常温で液状の魚油以外の油は、合計で、本発明の軟カプセル1粒当たりに、好ましくは、20mg以上配合することができる。さらに好ましくは、20〜60mg、さらに好ましくは40〜60mgである。このような油は、DHA濃縮精製魚油とEPA精製魚油とを混合する際に共に混合することができる。 Oils other than fish oil that is liquid at room temperature, such as rice germ oil, can be blended preferably in an amount of 20 mg or more per one soft capsule of the present invention. More preferably, it is 20-60 mg, More preferably, it is 40-60 mg. Such oils can be mixed together when mixing DHA concentrated refined fish oil and EPA refined fish oil.
本発明の軟カプセル中には、DHA及びEPAを含有する魚油と、上記の常温で液状の油以外にも、他の油溶性の健康成分や、抗酸化剤などを添加してもよい。このような成分としては、例えば、セサミン、エピセサミン、セサミノール、エピセサミノール、セサモリン等のセサミン類、α−トコフェロール、β−トコフェロール、γ−トコフェロール、δ−トコフェロール、ε−トコフェロール、ξ−トコフェロール、η−トコフェロール、トコフェロールエステル(酢酸トコフェロール等)のトコフェロール類、β−カロチン、カンタキサンチン、アスタキサンチン等のカロテノイド類、フラボン誘導体、フィロズルシン類、コウジ酸、没食子酸誘導体、カテキン類、フキ酸、ゴシポール、ピラジン誘導体、セサモール、グァヤオール、グァヤク酸、p−クマリン酸、ノールジヒドログァヤテッチク酸、ステロール類、テルペン類、核酸塩基類、リグナン類などの天然の抗酸化成分、及びアスコルビン酸パルミチン酸エステル、アスコルビン酸ステアリン酸エステル、ブチルヒドロキシアニソール(BHA)、ブチルヒドロキシトルエン(BHT)、モノ−t−ブチルヒドロキノン(TBHQ)、4−ヒドロキシメチル−2,6−ジ−t−ブチルフェノール(HMBP)に代表されるような合成抗酸化剤が挙げられる。特に、セサミン類は、好ましい化合物の一種である。 In addition to the fish oil containing DHA and EPA and the oil that is liquid at room temperature, other oil-soluble health ingredients, antioxidants, and the like may be added to the soft capsule of the present invention. Examples of such components include sesamin such as sesamin, episesamin, sesaminol, episesaminol, sesamorin, α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, ε-tocopherol, ξ-tocopherol, η-tocopherol, tocopherol esters (tocopherol acetate, etc.) tocopherols, β-carotene, canthaxanthin, astaxanthin and other carotenoids, flavone derivatives, phyllosilsins, kojic acid, gallic acid derivatives, catechins, fucic acid, gossypol, pyrazine Natural antioxidant components such as derivatives, sesamol, guaiaol, guaiacic acid, p-coumaric acid, nordihydroguayatic acid, sterols, terpenes, nucleobases, lignans, and ascorbic acid Palmitic acid ester, ascorbic acid stearic acid ester, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), mono-t-butylhydroquinone (TBHQ), 4-hydroxymethyl-2,6-di-t-butylphenol (HMBP) Synthetic antioxidants represented by In particular, sesamin is one of the preferred compounds.
セサミン類は、ゴマに含有されるリグナン化合物の一種であり、血中コレステロール低下作用及び血中中性脂質低下作用、肝機能改善作用、活性酸素消去作用、Δ5不飽和化酵素阻害作用、過酸化脂質生成抑制作用、抗高血圧作用、悪酔防止作用、乳癌抑制作用等の種々の生理活性が報告されている。本願明細書において、セサミン類とは、セサミン及びその類縁体を含む一連の化合物の総称である。例えば、上記のセサミン、エピセサミン、セサミノール、エピセサミノール、セサモリン等が含まれ、これらの立体異性体又はラセミ体を単独で、または混合して用いることができる。また、セサミン類の代謝体(例えば、特開2001−139579号公報に記載)も、効果を有する限り、本願明細書におけるセサミン類として使用することができる。セサミン類は、その形態や製造方法等によって何ら制限されない。例えば、セサミンを選択した場合には、市販の胡麻油(液状)をそのまま用いることもできるし、胡麻油から公知の方法(例えば、特開平4−9931号公報に記載された方法)によって抽出したセサミン(セサミン抽出物または濃縮物という)を用いることもできる。後者の方が、必要量をカプセル中に含有させやすく、消費者にとって摂取しやすいので好ましい。セサミン抽出物(またはセサミン濃縮物)は、公知の手段、例えば活性白土処理等により無味無臭としてもよい。セサミン類の濃縮物における濃縮の度合いは、用いるセサミン類の種類などに応じて適宜設定すればよいが、通常、セサミン類が総量で1w/w%以上となるように濃縮されたセサミン類濃縮物を用いるのが好ましい。セサミン類濃縮物中のセサミン類総含量は、20w/w%以上がより好ましく、さらに50w/w%以上が好ましく、さらに70w/w%以上が好ましく、90w/w%以上まで濃縮(精製)されたものが最適である。セサミン類の含有量は、HPLC法等の公知のいずれかの方法を用いて測定できる。HPLC法に関しては、例えば、特開2009−155312号公報に記載の方法等を参考にすることができる。 Sesamin is a kind of lignan compound contained in sesame seeds, blood cholesterol lowering action and blood neutral lipid lowering action, liver function improving action, active oxygen scavenging action, Δ5 desaturase inhibiting action, peroxidation Various physiological activities such as an adipogenesis inhibitory action, an antihypertensive action, a sickness prevention action, and a breast cancer inhibitory action have been reported. In the present specification, sesamin is a general term for a series of compounds including sesamin and its analogs. For example, the above-mentioned sesamin, episesamin, sesaminol, episesaminol, sesamoline and the like are included, and these stereoisomers or racemates can be used alone or in combination. In addition, metabolites of sesamins (for example, described in JP-A-2001-139579) can also be used as sesamins in the present specification as long as they have an effect. Sesamin is not limited by its form or production method. For example, when sesamin is selected, commercially available sesame oil (liquid) can be used as it is, or sesamin extracted from sesame oil by a known method (for example, a method described in JP-A-4-9931) Sesamin extract or concentrate) can also be used. The latter is preferable because the necessary amount is easily contained in the capsule and is easily consumed by consumers. The sesamin extract (or sesamin concentrate) may be made tasteless and odorless by known means, for example, activated clay treatment. The degree of concentration in the sesamin concentrate may be appropriately set according to the type of sesamin used, etc., but usually the sesamin concentrate concentrated so that the total amount of sesamin is 1 w / w% or more. Is preferably used. The total sesamin content in the sesamin concentrate is preferably 20 w / w% or more, more preferably 50 w / w% or more, further preferably 70 w / w% or more, and concentrated (purified) to 90 w / w% or more. The one is the best. The content of sesamin can be measured using any known method such as HPLC. Regarding the HPLC method, for example, the method described in JP2009-155531A can be referred to.
出願人は、セサミン類とビタミンE(トコフェロール類)とを組み合わせることにより、相乗的な抗疲労効果が得られることを見出している(国際公開第2009/038089号明細書)。したがって、本発明の軟カプセル中に、セサミン類とビタミンEとの組合せをさらに配合することは好ましい。 The applicant has found that a synergistic anti-fatigue effect can be obtained by combining sesamin and vitamin E (tocopherols) (WO 2009/038089). Therefore, it is preferable to further blend a combination of sesamin and vitamin E into the soft capsule of the present invention.
また、出願人は、セサミン類とともに、γ−オリザノール(米胚芽油に含まれる)を併用することで、セサミン類の生理作用、例えば、抗疲労作用が顕著に高まることを見出した(特開2009−073749号公報)。更に、出願人は、セサミン類を、γ−オリザノール(米胚芽油に含まれる)と組み合わせることにより、セサミン類の体内吸収が促進されることを見出し、出願を行った(特願2012−135034号(国際公開第2013/187391号参照))。したがって、本発明の軟カプセル中に、セサミン類とγ−オリザノール(または米胚芽油)との組合せを配合することは好ましい。 In addition, the applicant has found that the physiological action of sesamin, for example, anti-fatigue action is remarkably increased by using γ-oryzanol (contained in rice germ oil) together with sesamin (Japanese Patent Laid-Open No. 2009). No. 073749). Furthermore, the applicant has found that the in vivo absorption of sesamin is promoted by combining sesamin with γ-oryzanol (contained in rice germ oil) and filed an application (Japanese Patent Application No. 2012-135034). (See International Publication No. 2013/187391)). Therefore, it is preferable to add a combination of sesamin and γ-oryzanol (or rice germ oil) in the soft capsule of the present invention.
したがって、本発明の軟カプセル中に含有させる最も好ましい例としては、DHA及びEPAを含有する精製魚油、米胚芽油(γ−オリザノールを含む)、セサミン類、及びビタミンEの組み合わせが挙げられる。セサミン類の好ましい配合量は、本発明の軟カプセル1粒当たりに、0.1〜10mgであり、さらに好ましくは1〜5mgである。ビタミンEの好ましい配合量は、本発明の軟カプセル1粒当たりに、0.35〜20mgであり、さらに好ましくは7〜18mg、最も好ましくは7〜11mgである。 Therefore, the most preferable example to be contained in the soft capsule of the present invention includes a combination of purified fish oil containing DHA and EPA, rice germ oil (including γ-oryzanol), sesamin, and vitamin E. The preferable blending amount of sesamin is 0.1 to 10 mg, more preferably 1 to 5 mg per soft capsule of the present invention. The preferred amount of vitamin E is 0.35 to 20 mg, more preferably 7 to 18 mg, and most preferably 7 to 11 mg per soft capsule of the present invention.
セサミン類やビタミンEは、粉末の状態のものを、魚油と魚油以外の液状の油とを混合する際に添加して、これらの油中に溶解させてもよいし、あるいは、油の混合工程の前に、予め、魚油および/または魚油以外の油中に溶解させておいてもよい。例えば、ビタミンEは、ビタミンE含有オイルとして市販されている。ビタミンE含有オイルの好ましい配合量は、オイル中のビタミンEの含有率にもよるが、例えば、本発明の軟カプセル1粒当たりに1〜50mgであり、さらに好ましくは20〜50mg、最も好ましくは30〜50mgである。 Sesamin and vitamin E may be added when mixing fish oil and liquid oil other than fish oil and dissolved in these oils, or the oil mixing step It may be dissolved in advance in fish oil and / or oil other than fish oil. For example, vitamin E is commercially available as a vitamin E-containing oil. The preferred amount of vitamin E-containing oil depends on the content of vitamin E in the oil, but is, for example, 1 to 50 mg, more preferably 20 to 50 mg, most preferably, per soft capsule of the present invention. 30-50 mg.
(軟カプセル)
軟カプセルは、日本薬局方に規定されるように、「有効成分に添加剤を加えたものを、グリセリン又はD−ソルビトールなどを加えて塑性を増したゼラチンなどの適切なカプセル基剤で、一定の形状に被包成形」したものをいう。カプセル基材(カプセル皮膜の材料)や、カプセル化の方法は、特に限定されず、通常の材料及び方法を用いればよい。例えば、日本薬局方に規定されるように「グリセリン又はD−ソルビトールなどを加えて塑性を増したゼラチン」を皮膜の材料として用いればよく、また、打ち抜き法(ロータリーダイ)などを用いてカプセル皮膜の成形と内容物の充填とを行えばよい。(Soft capsule)
Soft capsules are, as prescribed by the Japanese Pharmacopoeia, “A combination of active ingredients with an appropriate capsule base such as gelatin with increased plasticity by adding glycerin or D-sorbitol, etc. "Encapsulated in the shape of". The capsule base material (capsule film material) and the encapsulation method are not particularly limited, and ordinary materials and methods may be used. For example, as specified in the Japanese Pharmacopoeia, “gelatin with increased plasticity by adding glycerin or D-sorbitol” may be used as a material for the film, and a capsule film using a punching method (rotary die) or the like. May be formed and the contents may be filled.
軟カプセルの形状や大きさは特に限定されず、カプセル内容物の量や、消費者の飲み込みやすさを考慮して設定する。軟カプセルの形状には、楕円形(オーバル)、長楕円形(オブロング)、球形(ラウンド)、なみだ形、特殊形(三角形、ハート形、ひし形等)などがあるが、なみだ形(しずく形と呼ばれることもある)の形状は、飲み込みやすく、また、容器から出した際に転がりにくいなど、消費者にとって扱いやすいと考えられるため、好ましい。軟カプセルの大きさは、飲みやすさを考慮すると、長径が17mm以下、短径が8mm以下程度であることが好ましい。軟カプセルの大きさ(長径、短径)の下限値は、カプセル内容物の量によって異なる。 The shape and size of the soft capsule are not particularly limited, and are set in consideration of the amount of capsule contents and ease of swallowing by the consumer. Soft capsule shapes include oval (oval), oblong (oblong), spherical (round), slender, special (triangle, heart, rhombus, etc.), but slender ( The shape (sometimes referred to as a drop shape) is preferable because it is easy to swallow and is easy to handle for consumers because it is difficult to roll when taken out of the container. The size of the soft capsule is preferably about 17 mm or less for the major axis and about 8 mm or less for the minor axis in consideration of ease of drinking. The lower limit of the soft capsule size (major axis, minor axis) varies depending on the amount of capsule contents.
本発明の軟カプセル1粒当たりに含まれる内容物の量(カプセル皮膜以外の重量)は、220mg〜260mgの範囲内とする。内容量が少なければ、健康成分の所望の量を1日当たりカプセル4粒で摂取する事が困難となるし、また、内容量が多すぎると、カプセルの全体の大きさが大きくなりすぎて、消費者が飲み込みにくくなるから好ましくない。軟カプセル1粒当たりの全体の重さ(内容物の量とカプセル皮膜の重量の合計)は、限定されないが、健康成分の所望量、飲み込みやすさ、及びカプセル皮膜の強度等を考慮すると、380mg〜420mg程度がよい。 The amount of content (weight other than the capsule film) contained per soft capsule of the present invention is in the range of 220 mg to 260 mg. If the internal volume is small, it will be difficult to take the desired amount of healthy ingredients in 4 capsules per day. If the internal volume is too large, the overall size of the capsule will become too large and consumed. It is not preferable because it becomes difficult for a person to swallow. The total weight per soft capsule (total amount of contents and capsule film weight) is not limited, but considering the desired amount of health ingredients, ease of swallowing, capsule film strength, etc., 380 mg About 420 mg is preferable.
本発明の軟カプセルは、ボトル容器などに詰めた後に、機能に関する表示を付して提供してもよい。機能の表示の方法には特別制限はないが、食品の包装、容器の面、食品の説明書、食品の広告等への表示が例示できる。本発明の軟カプセルが有する機能の例は、心血管リスク低減、中性脂肪低下作用、関節リウマチ症状緩和作用、加齢黄斑変性症発生リスク低減、認知機能低下抑制効果等が挙げられる。 The soft capsule of the present invention may be provided with a display regarding the function after being packed in a bottle container or the like. There are no particular restrictions on the method of displaying the function, but examples include display on food packaging, container surfaces, food instructions, food advertisements, and the like. Examples of the functions of the soft capsule of the present invention include cardiovascular risk reduction, neutral fat reduction action, rheumatoid arthritis symptom reduction action, age-related macular degeneration development risk reduction, cognitive function reduction suppression effect, and the like.
以下に実施例に基づいて本発明の説明をするが、本発明はこれらの実施例に限定されるものではない。 The present invention will be described below based on examples, but the present invention is not limited to these examples.
(参考例)
濃縮度合いの違いによるDHA濃縮精製魚油中のDHA含有率とEPA含有率の違いを表1に示す。魚油はマグロの頭部から採取し、リパーゼを用いてDHA以外の脂肪酸を除去する方法によりDHAを濃縮した。(Reference example)
Table 1 shows the difference in DHA content and EPA content in the DHA-concentrated and refined fish oil depending on the degree of concentration. Fish oil was collected from the tuna head, and DHA was concentrated by a method of removing fatty acids other than DHA using lipase.
なお、魚油中のDHA及びEPAの量は、以下の方法に従って測定した:
A.試料の前処理
魚油が軟カプセル中に含まれる場合には、中味液を注射針付きシリンジ等で取り出し、測定に供した。The amount of DHA and EPA in fish oil was measured according to the following method:
A. Pretreatment of sample When fish oil was contained in a soft capsule, the content liquid was taken out with a syringe with an injection needle or the like and subjected to measurement.
試料約50mgを50ml共栓付平底フラスコに正しく量り取り、N/2水酸化ナトリウム−メタノール溶液6mlを加え、還流冷却器を付けて水浴上で30分間沸騰させた後、三フッ素ホウ素メタノール錯体−メタノール溶液7mlを冷却器上部から加え、5分間沸騰させた後、更にヘキサン5mlを冷却器上部から加え、1分間沸騰させた。加熱を止め、フラスコを冷却器から外し、冷後ヘキサン層がフラスコの首に達するまで塩化ナトリウム飽和水溶液を加えた。約1mlのヘキサン溶液を試験管に移し少量の硫酸ナトリウム(無水)を加え、脱水したものを試料溶液とした。 About 50 mg of a sample was weighed correctly into a 50 ml flat-bottomed flask, added with 6 ml of N / 2 sodium hydroxide-methanol solution, boiled on a water bath for 30 minutes with a reflux condenser, and then trifluorinated boron methanol complex- 7 ml of methanol solution was added from the upper part of the condenser and boiled for 5 minutes, and then 5 ml of hexane was further added from the upper part of the condenser and boiled for 1 minute. Heating was stopped, the flask was removed from the condenser, and after cooling, saturated aqueous sodium chloride was added until the hexane layer reached the neck of the flask. About 1 ml of hexane solution was transferred to a test tube, a small amount of sodium sulfate (anhydrous) was added, and the dehydrated sample solution was used.
B.ガスクロマトグラフィー条件・カラム:J&W Scientific DB−WAX 30m×0.25mmI.D.,0.25μm
・検出器:FID
・キャリアーガス:He(1.5ml/min)
・カラム温度:140℃(1min)→3℃/min→230℃(30min)
・注入口温度:270℃
・検出器温度:270℃
・試料溶液注入量:3μl
C.計算方法および表示
ピーク面積の総和(溶媒のピーク面積は除く)に対するDHAおよびEPAのそれぞれのピーク面積の百分率をもって、脂肪酸組成中のDHA含量(%)およびEPA含量(%)とした。B. Gas Chromatography Conditions / Column: J & W Scientific DB-WAX 30m × 0.25mmI. D. , 0.25 μm
・ Detector: FID
-Carrier gas: He (1.5 ml / min)
Column temperature: 140 ° C. (1 min) → 3 ° C./min→230° C. (30 min)
・ Inlet temperature: 270 ° C
-Detector temperature: 270 ° C
Sample solution injection volume: 3 μl
C. Calculation method and display DHA content (%) and EPA content (%) in the fatty acid composition were percentages of the peak areas of DHA and EPA with respect to the total peak area (excluding the peak area of the solvent).
前述の魚油を使い、以下の表2に示す組成(軟カプセル1粒当たり、単位mg)に従って加温下で撹拌混合し、軟カプセル用の内容物を調製した。EPA濃縮精製魚油としては、市販の精製濃縮魚油を用いた。ビタミンE含有オイルおよび米胚芽油についても市販品を用いた。
Using the aforementioned fish oil, the contents for soft capsules were prepared by stirring and mixing under heating in accordance with the composition shown in Table 2 below (unit per mg of soft capsule). Commercially available purified concentrated fish oil was used as the EPA concentrated purified fish oil. Commercial products were also used for vitamin E-containing oil and rice germ oil.
これらを用いて、ロータリーダイにより、なみだ形の軟カプセルを製造した。得られた軟カプセル1粒当たりの皮膜の重量は、いずれも160mgであった(ゼラチン123mg、グリセリン37mg)。軟カプセル全体の重量(1粒当たり)は、参考品が398mg、本発明品が395mgであり、大きさは、いずれも、長径15mm、短径7mmであった。 Using these, a fluted soft capsule was produced by a rotary die. The weight of the film per one soft capsule obtained was 160 mg (gelatin 123 mg, glycerin 37 mg). The total weight (per capsule) of the soft capsules was 398 mg for the reference product and 395 mg for the product of the present invention, and the sizes were 15 mm for the major axis and 7 mm for the minor axis.
参考品と本発明品とは、いずれも、4粒当たりにDHAを300mg以上、EPAを100mg以上、セサミンを10mg以上、ビタミンEを40mg以上含んでいた。これらに加えて、本発明品は、さらにγ−オリザノールを10mg以上含んでいた。 Each of the reference product and the product of the present invention contained 300 mg or more of DHA, 100 mg or more of EPA, 10 mg or more of sesamin, and 40 mg or more of vitamin E per 4 tablets. In addition to these, the product of the present invention further contained 10 mg or more of γ-oryzanol.
本発明品では、DHAの含有率が50%以上となるように濃縮された魚油を、EPA精製魚油と組み合わせることにより、参考品に対してカプセル1粒当たりの重量を大きくすることなく、参考品と同程度の量のDHA、EPAに加えて、さらに米胚芽油(健康成分であるγ−オリザノールを含む)を軟カプセル中に含有させることができた。 In the product of the present invention, the fish oil concentrated so that the DHA content is 50% or more is combined with the EPA refined fish oil without increasing the weight per capsule of the reference product. In addition to DHA and EPA in the same amount as in Example 1, rice germ oil (including γ-oryzanol as a health ingredient) could be further contained in the soft capsule.
(実施例2)
前述の魚油3を用い、以下の表3に示す組成(軟カプセル1粒当たり、単位mg)に従って、内容物重量が220〜260mgで、製剤重量が380〜420mgの軟カプセルを製造した。EPA精製魚油、ビタミンE含有オイルおよび米胚芽油は市販品を用いた。製造方法は、実施例1に準じた。(Example 2)
Using the aforementioned fish oil 3, soft capsules having a content weight of 220 to 260 mg and a preparation weight of 380 to 420 mg were produced according to the composition shown in Table 3 below (unit of mg per soft capsule). Commercially available EPA refined fish oil, vitamin E-containing oil and rice germ oil were used. The production method was in accordance with Example 1.
得られた軟カプセルは、いずれも、4粒当たりにDHAを300mg以上、EPAを100mg以上含んでいた。また、液状の魚油以外の油を、カプセル1粒当たり約20〜60mg程度含んでおり、それでいて、服用しやすい大きさであった。 All of the obtained soft capsules contained 300 mg or more of DHA and 100 mg or more of EPA per 4 tablets. Moreover, it contained about 20-60 mg of oil other than liquid fish oil per capsule, and it was a size that was easy to take.
Claims (11)
ドコサヘキサエン酸の含有率が50%以上となるように濃縮された魚油と、エイコサペンタエン酸の含有率が15%以上である魚油と、これら以外の常温で液状の油とを混合すること、
混合した油を軟カプセルの皮膜で包んで、内容量(カプセル皮膜以外の重量)が、220mg〜260mgの軟カプセルとすること、
を含む、上記方法。Production of soft capsules containing a fish oil containing 75 mg or more of docosahexaenoic acid and eicosapentaenoic acid per soft capsule, and further containing oil other than liquid fish oil at room temperature and having a weight other than the capsule film of 220 mg to 260 mg A method,
Mixing fish oil concentrated so that the content of docosahexaenoic acid is 50% or more, fish oil having a content of eicosapentaenoic acid of 15% or more, and liquid oil at room temperature other than these,
Wrapping the mixed oil with a soft capsule film to make a soft capsule having an inner volume (weight other than the capsule film) of 220 mg to 260 mg,
Including the above method.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013204885 | 2013-09-30 | ||
JP2013204885 | 2013-09-30 | ||
PCT/JP2014/076042 WO2015046563A1 (en) | 2013-09-30 | 2014-09-30 | Soft capsule containing dha and epa |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2015046563A1 true JPWO2015046563A1 (en) | 2017-03-09 |
JP6450317B2 JP6450317B2 (en) | 2019-01-09 |
Family
ID=52743684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015539453A Active JP6450317B2 (en) | 2013-09-30 | 2014-09-30 | Soft capsule containing DHA and EPA |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP6450317B2 (en) |
CN (1) | CN105764499A (en) |
TW (1) | TWI681782B (en) |
WO (1) | WO2015046563A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017002015A (en) * | 2015-06-16 | 2017-01-05 | 北海道水産工業株式会社 | Supplement and production method thereof |
CN112890197A (en) * | 2021-03-10 | 2021-06-04 | 湖南文理学院 | Fish oil product with health promotion effect |
WO2023223943A1 (en) * | 2022-05-16 | 2023-11-23 | サントリーホールディングス株式会社 | Vascular endothelium function-improving composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08134026A (en) * | 1994-10-20 | 1996-05-28 | Prospa Bv | Salt of aminoalcohol and medicinal prescription containing same |
JPH10101550A (en) * | 1996-09-25 | 1998-04-21 | Asahi Chem Ind Co Ltd | Film for soft capsule |
JP2005535733A (en) * | 2002-07-08 | 2005-11-24 | アドバンスト ビジョン リサーチ | EPA and DHA enriched omega-3 supplements for the treatment of dry eye, meibomian adenitis and xerostomia |
JP2009073749A (en) * | 2007-09-19 | 2009-04-09 | Suntory Ltd | COMPOSITION CONTAINING SESAMIN COMPOUNDS AND gamma-ORYZANOL |
-
2014
- 2014-09-30 CN CN201480065091.5A patent/CN105764499A/en active Pending
- 2014-09-30 WO PCT/JP2014/076042 patent/WO2015046563A1/en active Application Filing
- 2014-09-30 JP JP2015539453A patent/JP6450317B2/en active Active
- 2014-09-30 TW TW103133995A patent/TWI681782B/en active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08134026A (en) * | 1994-10-20 | 1996-05-28 | Prospa Bv | Salt of aminoalcohol and medicinal prescription containing same |
JPH10101550A (en) * | 1996-09-25 | 1998-04-21 | Asahi Chem Ind Co Ltd | Film for soft capsule |
JP2005535733A (en) * | 2002-07-08 | 2005-11-24 | アドバンスト ビジョン リサーチ | EPA and DHA enriched omega-3 supplements for the treatment of dry eye, meibomian adenitis and xerostomia |
JP2009073749A (en) * | 2007-09-19 | 2009-04-09 | Suntory Ltd | COMPOSITION CONTAINING SESAMIN COMPOUNDS AND gamma-ORYZANOL |
Non-Patent Citations (1)
Title |
---|
DHA&EPA+セサミンE, サントリーウェルネス[ONLINE], JPN6018019903, 23 August 2013 (2013-08-23), ISSN: 0003807293 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015046563A1 (en) | 2015-04-02 |
TWI681782B (en) | 2020-01-11 |
TW201526925A (en) | 2015-07-16 |
CN105764499A (en) | 2016-07-13 |
JP6450317B2 (en) | 2019-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Design of foods with bioactive lipids for improved health | |
JP7007010B2 (en) | Lipid-containing composition and its usage | |
RU2396073C2 (en) | Oral composition for skin improvement | |
ES2351141B1 (en) | FUNCTIONAL OILS BASED ON OLIVE OIL. | |
JPWO2006059730A1 (en) | Composition for reducing body fat | |
WO2006117164A1 (en) | Nutritional supplement or functional food comprising oil combination | |
JP2006342286A (en) | Oil and fat composition | |
JP6450317B2 (en) | Soft capsule containing DHA and EPA | |
AU2018302797A1 (en) | Compositions comprising thymoquinone and omega-3 fatty acids | |
JP2014237680A (en) | Plant extract and pufa combination | |
JP2016533716A (en) | Edible lipid composition comprising stearidonic acid and olive oil | |
JP6537975B2 (en) | Composition containing high sesamin | |
JP5735576B2 (en) | Composition containing coenzyme Q10 | |
JP5683768B2 (en) | Composition containing coenzyme Q10 | |
CN110139645A (en) | For preventing and/or treating cachectic omega-3 fatty acid composition | |
US20210369668A1 (en) | Composition exhibiting enhanced oxidative stability | |
RU2211043C2 (en) | Composition for preparing medicinal forms and enrichment of foodstuffs promoting to correction of disturbances in lipid metabolism, prophylaxis and treatment of atherosclerosis | |
Prakash et al. | Plants based rich sources of polyunsaturated fatty acids: A comprehensive review | |
US20180110748A1 (en) | Composition for reducing or suppressing increase in neutral fat level containing n-3 unsaturated fatty acid, and use of n-3 unsaturated fatty acid in production of same composition | |
JP2018168139A (en) | Composition for reducing neutral fat values or inhibiting a rise thereof, containing n-3 unsaturated fatty acid, and use of n-3 unsaturated fatty acid in the production of the composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170926 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180724 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181207 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6450317 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |